BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 16640655)

  • 1. Interleukin-6 trans-signalling in chronic inflammation and cancer.
    Scheller J; Ohnesorge N; Rose-John S
    Scand J Immunol; 2006 May; 63(5):321-9. PubMed ID: 16640655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer.
    Rose-John S; Scheller J; Elson G; Jones SA
    J Leukoc Biol; 2006 Aug; 80(2):227-36. PubMed ID: 16707558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-6 transsignaling: the in vivo consequences.
    Jones SA; Richards PJ; Scheller J; Rose-John S
    J Interferon Cytokine Res; 2005 May; 25(5):241-53. PubMed ID: 15871661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-6 biology is coordinated by membrane bound and soluble receptors.
    Rose-John S
    Acta Biochim Pol; 2003; 50(3):603-11. PubMed ID: 14515143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The soluble Interleukin 6 receptor: generation and role in inflammation and cancer.
    Chalaris A; Garbers C; Rabe B; Rose-John S; Scheller J
    Eur J Cell Biol; 2011; 90(6-7):484-94. PubMed ID: 21145125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model.
    Matsumoto S; Hara T; Mitsuyama K; Yamamoto M; Tsuruta O; Sata M; Scheller J; Rose-John S; Kado S; Takada T
    J Immunol; 2010 Feb; 184(3):1543-51. PubMed ID: 20042582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The soluble IL-6 receptors: serum levels and biological function.
    Montero-Julian FA
    Cell Mol Biol (Noisy-le-grand); 2001 Jun; 47(4):583-97. PubMed ID: 11502067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses.
    Müller-Newen G; Küster A; Hemmann U; Keul R; Horsten U; Martens A; Graeve L; Wijdenes J; Heinrich PC
    J Immunol; 1998 Dec; 161(11):6347-55. PubMed ID: 9834125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors influencing the effect of the soluble IL-6 receptor on IL-6 responses in HepG2 hepatocytes.
    Paysant J; Blanqué R; Vasse M; Soria C; Soria J; Gardner CR
    Cytokine; 2000 Jun; 12(6):774-9. PubMed ID: 10843763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-6 trans-signaling in inflammatory bowel disease.
    Mitsuyama K; Sata M; Rose-John S
    Cytokine Growth Factor Rev; 2006 Dec; 17(6):451-61. PubMed ID: 17045835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-6 signalling in juvenile idiopathic arthritis is limited by proteolytically cleaved soluble interleukin-6 receptor.
    Peake NJ; Khawaja K; Myers A; Nowell MA; Jones SA; Rowan AD; Cawston TE; Foster HE
    Rheumatology (Oxford); 2006 Dec; 45(12):1485-9. PubMed ID: 16690760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-6/IL-6 receptor system and its role in physiological and pathological conditions.
    Mihara M; Hashizume M; Yoshida H; Suzuki M; Shiina M
    Clin Sci (Lond); 2012 Feb; 122(4):143-59. PubMed ID: 22029668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-6 receptor signaling. I. gp80 and gp130 receptor interaction in the absence of interleukin-6.
    Gaillard JP; Mani JC; Liautard J; Klein B; Brochier J
    Eur Cytokine Netw; 1999 Mar; 10(1):43-8. PubMed ID: 10210772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic strategies for targeting the IL-6/STAT3 cytokine signaling pathway in inflammatory bowel disease.
    Mitsuyama K; Matsumoto S; Masuda J; Yamasakii H; Kuwaki K; Takedatsu H; Sata M
    Anticancer Res; 2007; 27(6A):3749-56. PubMed ID: 17970038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of interleukin-6-transsignaling via gp130-Fc in hemorrhagic shock and sepsis.
    Mees ST; Toellner S; Marx K; Faendrich F; Kallen KJ; Schroeder J; Haier J; Kahlke V
    J Surg Res; 2009 Dec; 157(2):235-42. PubMed ID: 19589542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-6 and its receptor: from bench to bedside.
    Scheller J; Rose-John S
    Med Microbiol Immunol; 2006 Dec; 195(4):173-83. PubMed ID: 16741736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer.
    Neurath MF; Finotto S
    Cytokine Growth Factor Rev; 2011 Apr; 22(2):83-9. PubMed ID: 21377916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viral Interleukin-6: Structure, pathophysiology and strategies of neutralization.
    Suthaus J; Adam N; Grötzinger J; Scheller J; Rose-John S
    Eur J Cell Biol; 2011; 90(6-7):495-504. PubMed ID: 21176991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No inhibition of IL-27 signaling by soluble gp130.
    Scheller J; Schuster B; Hölscher C; Yoshimoto T; Rose-John S
    Biochem Biophys Res Commun; 2005 Jan; 326(4):724-8. PubMed ID: 15607729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis.
    Nowell MA; Richards PJ; Fielding CA; Ognjanovic S; Topley N; Williams AS; Bryant-Greenwood G; Jones SA
    Arthritis Rheum; 2006 Jul; 54(7):2084-95. PubMed ID: 16802343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.